Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
Approval decisions are looming for an excessive underarm sweating project, and Opdivo plus Yervoy in MSI-high colorectal cancer.
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.